Clinical Trial

Efficacy and Safety of the DTT106 in the Treatment of Erectile Dysfunction Associated With Benign Prostatic Hyperplasia

Study acronym: AUSTRÁLIA
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated February 20, 2024 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to assess the safety and efficacy of the DTT106 in the treatment of erectile dysfunction associated with benign prostatic hyperplasia
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-02-16.
Trial Details
NCT Number NCT06264414
Lead Sponsor EMS
Conditions Prostatic Hyperplasia, Benign, Erectile Dysfunction
Enrollment 262 participants
Start Date 2025-02
Primary Completion 2026-06 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2024-02-20